SRX Global says ARMR-100 fentanyl vaccine generates immune response in Phase 1/2 trial

• SRX Global issued a shareholder update on ARMR Sciences’ ongoing Phase 1/2 trial of ARMR-100, a fentanyl-targeting vaccine candidate.
• Interim results have already been presented in the update, showing the study has generated an anti-fentanyl immune response in humans.
• Safety has remained favorable so far, with no vaccine-related severe adverse events reported.
• ARMR has begun the fentanyl challenge portion of the study, with additional data expected as later cohorts progress.
• A new Department of War contract and FDA MIDD program acceptance could support ARMR’s regulatory strategy and development timeline.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SRX Global Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609030815PRIMZONEFULLFEED9820533) on September 03, 2026, and is solely responsible for the information contained therein.